May 2025 in “Galen Medical Journal” Psoriasis affects 2-3% of the global population and involves immune dysregulation, keratinocyte dysfunction, and genetic/epigenetic changes, with comorbidities like psoriatic arthritis and cardiovascular disease. Recent advances using single-cell RNA sequencing and transcriptomics have identified key mechanisms such as GSDME-mediated pyroptosis and IL-23/IL-17 axis activation. Targeted therapies, including IL-17 inhibitors like secukinumab and IL-23 inhibitors like risankizumab, show promise, while novel treatments like hyperforin and Deu@Cal microneedles are in early stages. Challenges include adverse events, treatment resistance, and personalization gaps. Future efforts focus on multi-omics integration and combination therapies to enhance precision medicine in psoriasis management.
144 citations
,
November 2020 in “Frontiers in immunology” Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.
January 2025 in “International Journal of Molecular Sciences” Psoriasis involves immune and genetic factors, and understanding these can improve treatments.
57 citations
,
April 2019 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata involves immune system imbalances that may lead to depression and anxiety.
February 2023 in “Research Square (Research Square)” Blocking IL-17 can reduce skin inflammation in a mouse model of pityriasis rubra pilaris.